Cargando…
GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition
Since December 2019, SARS-CoV-2 has spread quickly worldwide, leading to more than 280 million confirmed cases, including over 5,000,000 deaths. Interestingly, coronaviruses were found to subvert and hijack autophagic process to allow their viral replication. Autophagy-modulating compounds thus rapi...
Autores principales: | Bestion, Eloïne, Zandi, Keivan, Belouzard, Sandrine, Andreani, Julien, Lepidi, Hubert, Novello, Marie, Rouquairol, Clara, Baudoin, Jean-Pierre, Rachid, Madani, La Scola, Bernard, Mege, Jean-Louis, Dubuisson, Jean, Schinazi, Raymond F., Mezouar, Soraya, Halfon, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778678/ https://www.ncbi.nlm.nih.gov/pubmed/35062337 http://dx.doi.org/10.3390/v14010132 |
Ejemplares similares
-
GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions
por: Brun, Sonia, et al.
Publicado: (2021) -
GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in
liver fibrosis through TGF-β1 inhibition
por: Bestion, Eloïne, et al.
Publicado: (2020) -
GNS561, a New Autophagy Inhibitor Active against Cancer Stem Cells in Hepatocellular Carcinoma and Hepatic Metastasis from Colorectal Cancer
por: Brun, Sonia, et al.
Publicado: (2021) -
Cell and Animal Models for SARS-CoV-2 Research
por: Bestion, Eloïne, et al.
Publicado: (2022) -
Update on Autophagy Inhibitors in Cancer: Opening up to a Therapeutic Combination with Immune Checkpoint Inhibitors
por: Bestion, Eloïne, et al.
Publicado: (2023)